{"id":70765,"date":"2026-05-12T10:53:49","date_gmt":"2026-05-12T10:53:49","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70765"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"cagrisema","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/cagrisema\/","title":{"rendered":"Mezcla CagriSema (Cagrilintida 5 mg + Semaglutida 5 mg)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es CagriSema?<\/h3>\n<p style=\"margin: 0;\"><strong>CagriSema<\/strong> es la combinaci\u00f3n coformulada de <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">cagrilintida<\/a> (an\u00e1logo de amilina de acci\u00f3n prolongada) y <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a> (agonista de GLP-1 de acci\u00f3n prolongada) en un solo vial liofilizado. Es el programa l\u00edder de Novo Nordisk en Fase 3 para la obesidad y produjo reducciones de peso corporal de aproximadamente 20\u201323% durante 68 semanas en el ensayo REDEFINE-1 \u2014 tama\u00f1os de efecto comparables a los de un triple agonista <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">retatrutide<\/a> achieved through the combination of two single-receptor agonists rather than a single multi-agonist molecule. Each vial contains 5\u00a0mg cagrilintide + 5\u00a0mg semaglutide for clinical studies use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Composici\u00f3n<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cagrilintide 5\u00a0mg + Semaglutide 5\u00a0mg por vial (proporci\u00f3n de masa 1:1, coformulado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>P\u00e9ptido total por vial<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">10\u00a0mg de masa total de p\u00e9ptidos (5\u00a0mg + 5\u00a0mg)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00fameros CAS de los componentes<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1415456-99-3 (cagrilintide) \/ 910463-68-2 (semaglutide)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Perfil de receptores<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Familia de receptores de amilina\/calcitonina (AMY1\/2\/3) <em>m\u00e1s<\/em> Receptor GLP-1 \u2014 complementarios mecan\u00edsticamente, sin superposici\u00f3n<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado coformulado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (cada componente verificado por HPLC, COA disponible bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Vida media (por componente)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cagrilintide ~159 horas; Semaglutide ~165 horas \u2014 ambos permiten una dosificaci\u00f3n subcut\u00e1nea semanal<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada). Ambos p\u00e9ptidos se reconstituyen simult\u00e1neamente desde el mismo vial.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es CagriSema?<\/h2>\n<p><strong>CagriSema<\/strong> es el nombre en desarrollo de Novo Nordisk para la combinaci\u00f3n de proporci\u00f3n fija de dos p\u00e9ptidos de acci\u00f3n prolongada en una \u00fanica formulaci\u00f3n subcut\u00e1nea: <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">cagrilintida<\/a> (el an\u00e1logo de amilina de acci\u00f3n prolongada, c\u00f3digo de desarrollo AM833) y <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a> (el agonista del receptor GLP-1 de acci\u00f3n prolongada comercializado como Ozempic y Wegovy como agente independiente). La combinaci\u00f3n es el programa l\u00edder de Fase 3 para la obesidad en el pipeline de Novo Nordisk y report\u00f3 los resultados del ensayo REDEFINE-1 en 2024\u20132025: aproximadamente una reducci\u00f3n del 20\u201323% en el peso corporal durante 68 semanas con la dosis semanal de 2.4\u00a0mg + 2.4\u00a0mg \u2014 efectos que sit\u00faan a CagriSema en el mismo rango que el agonista triple de receptores <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">retatrutide<\/a> while taking a completely different pharmacological route. The strategic rationale for CagriSema rests on the <strong>mecanismos complementarios, no superpuestos<\/strong> of its two component peptides. GLP-1 receptor agonists (semaglutide) act predominantly on hypothalamic arcuate-nucleus POMC neurons (central appetite regulation) and pancreatic beta-cells (glucose-dependent insulin secretion). Amylin\/calcitonin receptor agonists (cagrilintide) act predominantly on brainstem area-postrema neurons (per-meal satiety reinforcement) and pancreatic alpha-cells (glucagon suppression). The two mechanisms are mechanistically additive rather than redundant, which is why the combination produces body-weight effects substantially greater than either component alone \u2014 demonstrated in the Phase 2 head-to-head data where CagriSema outperformed both cagrilintide monotherapy and semaglutide monotherapy. This pharmaceutical-grade CagriSema co-formulation contains <strong>5\u00a0mg de cagrilintide + 5\u00a0mg de semaglutide por vial<\/strong> en una proporci\u00f3n de masa 1:1 que coincide con la proporci\u00f3n de dosis fija utilizada en el programa cl\u00ednico de Fase 3. Ambos componentes est\u00e1n premezclados en el mismo vial liofilizado; la reconstituci\u00f3n con agua bacteriost\u00e1tica produce una soluci\u00f3n de trabajo que contiene ambos p\u00e9ptidos simult\u00e1neamente. Este enfoque elimina la necesidad de combinar viales separados en el laboratorio. CagriSema <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as of current literature; regulatory submission and review are ongoing. For deeper detail on each component, see our individual <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">Cagrilintida<\/a> y <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> p\u00e1ginas de productos. <\/p>\n<h2>Mechanism of Action \u2014 Complementary Dual-Receptor Pharmacology<\/h2>\n<p>What makes CagriSema mechanistically distinctive among current metabolic-compounds is that the two component peptides activate <strong>entirely different receptor families with non-overlapping central and peripheral mechanisms<\/strong> \u2014 achieving multi-axis pharmacology through combination rather than through engineering a single multi-agonist molecule like tirzepatide or retatrutide:<\/p>\n<ul>\n<li><strong>GLP-1 receptor arm (semaglutide) \u2014 central appetite regulation and glycaemic control<\/strong> \u2014 Semaglutide activates the GLP-1 receptor on hypothalamic arcuate-nucleus POMC neurons (suppressing food intake via the central appetite system), pancreatic beta-cells (glucose-dependent insulin secretion), pancreatic alpha-cells (glucagon suppression), and gastric vagal afferents (delayed gastric emptying). This arm provides the canonical incretin pharmacology that semaglutide and other GLP-1 agonists are known for in published studies and approved clinical use.<\/li>\n<li><strong>Amylin \/ calcitonin receptor arm (cagrilintide) \u2014 brainstem satiety and per-meal feedback<\/strong> \u2014 Cagrilintide activates the amylin receptor heterodimers (AMY1, AMY2, AMY3 \u2014 calcitonin receptor + RAMP1\/2\/3) located densely in the brainstem area postrema, a CNS region that lacks a blood-brain barrier. This produces per-meal satiety reinforcement on a different temporal pattern than GLP-1\u2019s tonic central appetite suppression. The amylin arm also delays gastric emptying via a partly distinct vagal pathway and suppresses postprandial glucagon at pancreatic alpha-cells.<\/li>\n<li><strong>Additive vs synergistic effect on body-weight phenotype<\/strong> \u2014 The Phase 2 head-to-head data are the cleanest evidence of additive (and possibly synergistic) pharmacology: cagrilintide monotherapy at 2.4\u00a0mg weekly produced ~10% body-weight reduction; semaglutide monotherapy at 2.4\u00a0mg weekly produced ~15%; the CagriSema combination at 2.4 + 2.4 mg produced ~20\u201323%. The net effect approaches or exceeds the sum of the individual effects, consistent with the mechanistic prediction that two non-overlapping satiety pathways activated simultaneously produce a stronger anorectic signal than either alone.<\/li>\n<\/ul>\n<p>Both peptides are acylated with fatty-diacid chains that bind reversibly to circulating serum albumin (cagrilintide uses a C20 chain via \u03b3-Glu-OEG-OEG; semaglutide uses C18 via \u03b3-Glu-AEEA-AEEA). The half-lives are well matched at ~159 hours (cagrilintide) and ~165 hours (semaglutide) \u2014 both supporting once-weekly subcutaneous dosing without divergent pharmacokinetics. This pharmacokinetic alignment is one of the design features that makes co-formulation in a single vial practical: the two components can be reconstituted, stored, and dosed together without compromising either\u2019s exposure profile. <\/p>\n<h2>Published Evidence<\/h2>\n<p>CagriSema co-formulation peptides are used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Combination obesity pharmacology<\/strong> \u2014 the lead programme: preclinical DIO rodent models, body-composition (DEXA\/MRI), food-intake assays, energy-expenditure characterisation; head-to-head against monotherapy arms (cagrilintide alone, semaglutide alone) to dissect the additive vs synergistic question (Enebo et al., Lancet 2021; REDEFINE-1 \/ REDEFINE-2 Phase 3 results)<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 glycaemic control, HbA1c surrogates, postprandial glucose dynamics in db\/db and high-fat-diet rodent models<\/li>\n<li><strong>Comparative multi-agonist studies<\/strong> \u2014 head-to-head with single-molecule multi-agonists including <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> (dual GLP-1\/GIP), <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (triple GLP-1\/GIP\/glucagon), <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">Mazdutida<\/a> (dual GLP-1\/glucag\u00f3n), y <a href=\"https:\/\/medsbase.com\/es\/survodutide\/\">Survodutida<\/a> (dual GLP-1\/glucag\u00f3n); la cuesti\u00f3n central es si la farmacolog\u00eda de combinaci\u00f3n de dos mol\u00e9culas tiene alguna ventaja sobre las mol\u00e9culas mono-multi-agonistas<\/li>\n<li><strong>Amylin \/ GLP-1 axis interaction studies<\/strong> \u2014 caracterizaci\u00f3n de mecanismos no superpuestos, disecci\u00f3n de circuitos centrales del apetito en el tronco encef\u00e1lico frente al hipot\u00e1lamo, ensayos de ocupaci\u00f3n simult\u00e1nea de receptores<\/li>\n<li><strong>Vaciamiento g\u00e1strico y fisiolog\u00eda posprandial<\/strong> \u2014 tiempo de vaciamiento g\u00e1strico bajo tratamiento combinado frente a individual, din\u00e1mica de glucosa posprandial, integraci\u00f3n del eje hormona-intestino<\/li>\n<li><strong>Energy expenditure studies<\/strong> \u2014 gasto energ\u00e9tico en reposo, cociente de intercambio respiratorio; la combinaci\u00f3n CagriSema produce un perfil distinto al de los multi-agonistas que contienen receptores de glucag\u00f3n (mazdutida, retatrutida) porque ninguno de sus componentes activa el receptor de glucag\u00f3n<\/li>\n<li><strong>Combination-pharmacology design studies<\/strong> \u2014 CagriSema como caso de estudio en la formulaci\u00f3n de p\u00e9ptidos m\u00faltiples en proporci\u00f3n fija, comparaci\u00f3n de la farmacocin\u00e9tica de la co-formulaci\u00f3n frente a viales separados administrados secuencialmente o conjuntamente.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio, consulte nuestras <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">Cagrilintida<\/a> y <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> p\u00e1ginas de producto para farmacolog\u00eda a nivel de componente, <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> como la principal alternativa mono-mol\u00e9cula triple-agonista, y <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> como el comparador dual GLP-1\/GIP. Explore el completo <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Configuraciones Disponibles<\/h2>\n<p>MedsBase almacena la mezcla CagriSema en una \u00fanica co-formulaci\u00f3n: <strong>5\u00a0mg de cagrilintide + 5\u00a0mg de semaglutide por vial<\/strong> at the clinical 1:1 mass ratio. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Composici\u00f3n del Vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg + 5 mg<\/strong> (cagri + sema)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard CagriSema studies blend \u2014 combination obesity, T2DM, and additive-pharmacology studies at the clinical 1:1 mass ratio<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both components are supplied at \u226599% HPLC purity (each verified individually) and pre-mixed in the same lyophilized vial. The 5\u00a0mg + 5\u00a0mg per vial composition supports approximately 2 weeks of clinical-equivalent dosing (2.4\u00a0mg + 2.4\u00a0mg weekly) per vial \u2014 a 10-vial pack covers approximately 20 weeks of studies at the Phase 3 maintenance dose. Compared with buying 10 vials of stand-alone Cagrilintide (5\u00a0mg) plus 10 vials of stand-alone Semaglutide (5\u00a0mg) separately, the co-formulated blend offers a modest cost saving and the practical convenience of single-vial reconstitution. <\/p>\n<h2>C\u00f3mo se compara \u2014 CagriSema frente a Retatrutida<\/h2>\n<p>CagriSema y <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> are the two leading multi-mechanism approaches to maximum-magnitude body-weight effect in current metabolic-peptide studies. They take fundamentally different design approaches: CagriSema combines two single-receptor agonists in a fixed-dose blend, while retatrutide engineers triple-receptor pharmacology into a single molecule. The two reach comparable Phase 2\/3 body-weight effect sizes through these distinct routes \u2014 the comparison is one of the most-cited in current obesity-pharmacology studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">CagriSema<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutida<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Enfoque de dise\u00f1o<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Combinaci\u00f3n de dos agonistas de receptor \u00fanico<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mol\u00e9cula \u00fanica triagonista<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + Amilina\/Calcitonina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + Glucag\u00f3n<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Componentes<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cagrilintida + Semaglutida<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mol\u00e9cula \u00fanica (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desarrollador<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Novo Nordisk<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eli Lilly<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efecto sobre el peso corporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~20\u201323% (REDEFINE-1, 68 semanas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24% (Fase 2, 48 semanas)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Alineaci\u00f3n de vida media<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~159 \/ ~165 horas (bien emparejadas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 d\u00edas (mol\u00e9cula \u00fanica, no necesita emparejamiento)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Amplitud del mecanismo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Apetito central + saciedad del tronco encef\u00e1lico + supresi\u00f3n del glucag\u00f3n<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Apetito central + lip\u00f3lisis mediada por GIP + gasto energ\u00e9tico impulsado por glucag\u00f3n<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Gasto energ\u00e9tico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modest (no glucagon arm)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Substantial (glucagon arm)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The pharmacological choice between CagriSema and retatrutide depends on the studies question. For studies interested in maximum body-weight effect with the cleanest receptor-selectivity profile (no off-target GIP or glucagon signalling), CagriSema is the preferred reference. For studies interested in the additional mechanism breadth that glucagon-receptor activation provides (energy expenditure, hepatic lipid mobilisation), retatrutide is the canonical comparator. The combination-vs-single-molecule design question is itself an active area of pharmaceutical studies \u2014 both approaches have reached late-stage development, and Phase 3 head-to-head trials are likely to inform the long-term winner. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> store lyophilized vials refrigerated at 2\u20138\u00a0\u00b0C in original packaging for short-term working stock. For unopened long-term storage, freeze at \u221220\u00a0\u00b0C. The lyophilized CagriSema co-formulation is stable under refrigeration for up to 24 months and at \u221220\u00a0\u00b0C for up to 36 months. Both component peptides have closely-matched stability profiles, so storage is governed by whichever peptide degrades first under given conditions \u2014 in practice, the two components are remarkably similar. Avoid freeze-thaw cycles on the lyophilized powder. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). Because the vial contains 10\u00a0mg total peptide mass (5\u00a0mg cagri + 5\u00a0mg sema), a 2.0\u00a0mL reconstitution yields a 5\u00a0mg\/mL total-peptide working concentration \u2014 equivalent to 2.5\u00a0mg\/mL of each individual component. Approximately 0.96\u00a0mL delivers a 2.4\u00a0mg + 2.4\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>ajuste<\/strong> shake \u2014 and allow 5\u201310 minutes for full dissolution (both peptides are acylated and dissolve more slowly than smaller unmodified peptides). A correctly reconstituted solution should be clear and colourless with no visible particles. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability of both components. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity and could disproportionately affect either component. Discard any vial showing cloudiness, precipitate, or discolouration. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is CagriSema used for in studies?<\/h3>\n<p>CagriSema is used in studies investigating the additive pharmacology of GLP-1 and amylin receptor activation, combination obesity pharmacology, type 2 diabetes preclinical models, comparative head-to-head studies against single-molecule multi-agonists (tirzepatide, retatrutide, mazdutide, survodutide), and combination-pharmacology design questions. It is the lead Phase 3 combination-pharmacology compound in current metabolic-peptide studies from Novo Nordisk. The pharmaceutical-grade CagriSema sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>What is in a CagriSema vial?<\/h3>\n<p>Cada vial contiene <strong>5\u00a0mg of cagrilintide and 5\u00a0mg of semaglutide<\/strong>, co-formulated and lyophilized together as a single powder. The 1:1 mass ratio matches the fixed-dose ratio used in the Phase 3 clinical CagriSema programme (2.4\u00a0mg + 2.4\u00a0mg weekly). Both peptides reconstitute simultaneously when bacteriostatic water is added. <\/p>\n<h3>How is CagriSema different from Cagrilintide alone or Semaglutide alone?<\/h3>\n<p>CagriSema combines both peptides in one vial. <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">Cagrilintide alone<\/a> activates only the amylin\/calcitonin receptor family and produces approximately 10% body-weight reduction in Phase 2 monotherapy studies. <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutide alone<\/a> activates only the GLP-1 receptor and produces approximately 15% body-weight reduction in Phase 3 monotherapy (STEP trials). The CagriSema combination produces approximately 20\u201323% \u2014 greater than either component alone, because the two mechanisms are non-overlapping (different receptors, different CNS sites, complementary peripheral effects). <\/p>\n<h3>How is CagriSema different from Retatrutide?<\/h3>\n<p>Both are leading multi-mechanism approaches to body-weight effect, but they take fundamentally different design routes. CagriSema combines two separate single-receptor agonists (cagrilintide + semaglutide) in one vial \u2014 combination pharmacology. <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> engineers triple-receptor pharmacology (GLP-1 + GIP + glucagon) into a single molecule. Both reach approximately 20\u201324% body-weight effect at maintenance dose in Phase 2\/3 studies, but through different receptor sets \u2014 CagriSema uses GLP-1 + amylin, retatrutide uses GLP-1 + GIP + glucagon. <\/p>\n<h3>Why combine the two peptides in a single vial?<\/h3>\n<p>Co-formulation has three practical advantages: (1) the half-lives of cagrilintide (~159 h) and semaglutide (~165 h) are well-matched, so a single weekly injection delivers both peptides on the same pharmacokinetic schedule; (2) reconstitution is simpler \u2014 one vial, one diluent volume, one withdrawal; (3) fixed-dose-ratio is straightforward because the dose ratio is set at manufacture and cannot drift between separate vial draws. The principal trade-off is that the dose ratio is fixed at 1:1 mass \u2014 for studies requiring different ratios, separate vials of <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">cagrilintida<\/a> y <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a> may be preferred. <\/p>\n<h3>What is the typical CagriSema dose?<\/h3>\n<p>Published Phase 3 clinical studies uses 2.4\u00a0mg cagrilintide + 2.4\u00a0mg semaglutide weekly as the maintenance dose, with a multi-month titration schedule starting at 0.25\u00a0mg + 0.25\u00a0mg. A vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL of each component (5\u00a0mg\/mL total peptide mass) \u2014 approximately 0.96\u00a0mL equals a clinical-equivalent 2.4\u00a0mg + 2.4\u00a0mg dose. <\/p>\n<h3>Is CagriSema FDA approved?<\/h3>\n<p>No. CagriSema is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The REDEFINE-1 (obesity) and REDEFINE-2 (T2DM) Phase 3 trials reported positive results in 2024\u20132025, but regulatory submission and review are ongoing. <\/p>\n<h3>How should CagriSema be stored?<\/h3>\n<p>Lyophilized vials: refrigerated at 2\u20138\u00a0\u00b0C for short-term working stock, or \u221220\u00a0\u00b0C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2\u20138\u00a0\u00b0C, use within 30 days. Do not freeze reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity and could disproportionately affect either component. Protect from direct light at all times. <\/p>\n<h3>How do I reconstitute CagriSema?<\/h3>\n<p>Follow the reconstitution procedure above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 5\u201310 minutes for full dissolution (both peptides are acylated and dissolve more slowly than smaller unmodified peptides). Do <strong>ajuste<\/strong> shake the vial. Both peptides reconstitute simultaneously from the same vial. A correctly reconstituted solution is clear and colourless with no visible particles. For a vial + 2.0\u00a0mL diluent, the working concentration is 2.5\u00a0mg\/mL of each peptide. <\/p>\n<h3>\u00bfQu\u00e9 configuraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries the CagriSema co-formulation in a single composition: 5\u00a0mg cagrilintide + 5\u00a0mg semaglutide per vial (1:1 mass ratio, lyophilized). The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. Each component is verified individually at \u226599% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can I buy CagriSema components separately instead?<\/h3>\n<p>Yes \u2014 MedsBase stocks both component peptides as stand-alone products: <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">Cagrilintida<\/a> in 5\u00a0mg and 10\u00a0mg vials, and <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> in 2\u201350\u00a0mg vials. Separate vials are useful if protocols require dose ratios other than the clinical 1:1 mass ratio, or if users want to dose cagrilintide and semaglutide independently. The co-formulated blend offers a small bundle saving and the convenience of single-vial reconstitution for protocols at the 1:1 clinical ratio. <\/p>\n<h3>Does CagriSema cause side reported effects?<\/h3>\n<p>The side-effect profile of CagriSema in Phase 3 is dominated by gastrointestinal findings shared with both component peptides: nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4\u20138 weeks of continuous dosing. The combined regimen does not produce qualitatively different side effects from either component alone \u2014 the GI-axis tolerability is roughly comparable to semaglutide monotherapy at equivalent doses. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media de CagriSema?<\/h3>\n<p>Ambos p\u00e9ptidos componentes tienen vidas medias plasm\u00e1ticas muy similares: cagrilintida ~159 horas (~6,5 d\u00edas) y semaglutida ~165 horas (~7 d\u00edas). Esta coincidencia es una de las caracter\u00edsticas de dise\u00f1o que hace pr\u00e1ctica la coformulaci\u00f3n en un solo vial: ambos p\u00e9ptidos se eliminan de la circulaci\u00f3n en el mismo plazo, lo que permite una dosificaci\u00f3n semanal sin farmacocin\u00e9tica divergente. El mecanismo de uni\u00f3n a la alb\u00famina (acilaci\u00f3n de \u00e1cido graso C20\/C18) es la base de la vida media prolongada en ambos p\u00e9ptidos. <\/p>\n<h3>How long does CagriSema take to show effects in preclinical studies?<\/h3>\n<p>Los efectos farmacodin\u00e1micos agudos sobre el vaciamiento g\u00e1strico, la saciedad por comida y la tolerancia a la glucosa son detectables horas despu\u00e9s de la primera dosis. Los efectos sobre el peso corporal en modelos de roedores con obesidad inducida por dieta (DIO) suelen ser estad\u00edsticamente significativos despu\u00e9s de 1-2 semanas de dosificaci\u00f3n semanal y contin\u00faan acumul\u00e1ndose hasta las 16-24 semanas. El efecto m\u00e1ximo sobre la composici\u00f3n corporal se desarrolla en 48-68 semanas, coincidiendo con la trayectoria de la Fase 3 del estudio REDEFINE-1. <\/p>\n<h3>\u00bfPuedo pedir CagriSema para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda CagriSema a todo el mundo desde nuestra red dedicada de env\u00edo de p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo de p\u00e9ptidos independiente. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Multi-Mechanism Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/cagrilintide\/\"><strong>Cagrilintida<\/strong><\/a> \u2014 An\u00e1logo de amilina de acci\u00f3n prolongada \u2014 el componente de amilina de CagriSema, viales independientes<\/li>\n<li><a href=\"\/es\/semaglutide\/\"><strong>Semaglutida<\/strong><\/a> \u2014 Agonista de GLP-1 de acci\u00f3n prolongada \u2014 el componente de GLP-1 de CagriSema, viales independientes<\/li>\n<li><a href=\"\/es\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Agonista triple de GLP-1\/GIP\/glucag\u00f3n \u2014 alternativa multimol\u00e9cula \u00fanica<\/li>\n<li><a href=\"\/es\/tirzepatide\/\"><strong>Tirzepatida<\/strong><\/a> \u2014 Agonista dual de GLP-1\/GIP \u2014 enfoque alternativo de m\u00faltiples mecanismos<\/li>\n<li><a href=\"\/es\/mazdutide\/\"><strong>Mazdutida<\/strong><\/a> \u2014 Coagonista dual de GLP-1\/glucag\u00f3n \u2014 alternativa derivada de oxintomodulina<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explora el panorama metab\u00f3lico de la farmacolog\u00eda combinada<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados de combinaci\u00f3n y m\u00faltiples mecanismos, incluyendo <a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">Cagrilintida<\/a> (amilina independiente), <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> (GLP-1 independiente), <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (agonista triple de mol\u00e9cula \u00fanica), y <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">Mazdutida<\/a> (dual GLP-1\/glucag\u00f3n). Gu\u00eda comparativa: <a href=\"https:\/\/medsbase.com\/es\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Combinaci\u00f3n coformulada de cagrilintida + semaglutida (1:1)<br \/>\n\u2705 Ambos p\u00e9ptidos en un solo vial (5 mg + 5 mg)<br \/>\n\u2705 Combinaci\u00f3n l\u00edder de Novo Nordisk en Fase 3 para obesidad<br \/>\n\u2705 Efecto de ~20\u201323% en el peso corporal (REDEFINE-1)<br \/>\n\u2705 Mecanismos complementarios de amilina + GLP-1<\/p>\n<p><strong>CagriSema<\/strong> es una mezcla coformulada de p\u00e9ptidos.<\/p>","protected":false},"featured_media":70943,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6284,6287,5441,3846],"class_list":["post-70765","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cagrilintide","product_tag-cagrisema","product_tag-peptide","product_tag-semaglutide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70765"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70943"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70765"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70765"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70765"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}